CoChat
Sign Up
Cited by 1,700Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCerebrospinal fluid and hydrocephalus

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

Open access
Hansson, Oskar, Zetterberg, Henrik, Buchhave, Peder, Londos, Elisabet, Blennow, Kaj, Minthon, Lennart·2006·The Lancet Neurology
DOI 10.1016/s1474-4422(06)70355-6
Open this paper in CoChat — free account

Abstract

Background Disease-modifying treatment strategies for Alzheimer's disease have led to an urgent need for biomarkers to identify the disease at a very early stage. Here, we assess the association between CSF biomarkers and incipient Alzheimer's in patients with mild cognitive impairment (MCI).Methods From a series of 180 consecutive patients with MCI, we assessed 137 who underwent successful lumbar puncture at baseline. Patients at risk of developing dementia were followed clinically for 4-6 years. Additionally, 39 healthy individuals, cognitively stable over 3 years, served as controls. We analysed CSF concentrations of beta amyloid(1-42) (Abeta42), total tau (T-tau), and phosphorylated tau (P-tau181) using Luminex xMAP technology.Findings During follow-up, 57 (42%) patients with MCI developed Alzheimer's disease, 21 (15%) developed other forms of dementia, and 56 (41%) remained cognitively stable for 5.2 years (range 4.0-6.8). A combination of CSF T-tau and Abeta42 at baseline yielded a sensitivity of 95% and a specificity of 83% for detection of incipient AD in patients with MCI. The relative risk of progression to Alzheimer's disease was substantially increased in patients with MCI who had pathological concentrations of T-tau and Abeta42 at baseline (hazard ratio 17.7, p<0.0001). The association between pathological CSF and progression to Alzheimer's disease was much stronger than, and independent of, established risk factors including age, sex, education, APOE genotype, and plasma homocysteine. The combination of T-tau and Abeta42/P-tau181 ratio yielded closely similar results (sensitivity 95%, specificity 87%, hazard ratio 19.8).Interpretation Concentrations of T-tau, P-tau181, and Abeta42 in CSF are strongly associated with future development of Alzheimer's disease in patients with MCI.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(06)70355-6

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Some patients with MCI or depression before AD have a more gradual progression to the disease and have pathologic Aβ and tau CSF level changes that are not affected by APOE allele status, while other forms of AD show a strong APOE association.

    “Furthermore, one study shows that some patients with MCI or depression before AD have a more gradual progression to the disease and that they have pathologic Aβ and tau cerebrospinal fluid (CSF) level changes that are not affected by APOE allele status, while the other forms of AD show a strong APOE association (46).”

    From Molecular subtyping of Alzheimer’s disease using RNA sequencing data reveals novel mechanisms and targets (2021) · cites this paper as [46]

  • Increased concentrations of extracellular soluble p-tau and t-tau constitute a reliable index of the intracellular NFT process in MCI due to AD and AD dementia.

    “Increased concentrations of extracellular soluble phosphorylated tau (p-tau) and total tau (t-tau) constitute a reliable index of this intracellular process in mild cognitive impairment due to AD2,3 and AD dementia.2,4”

    From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [3]

  • Majority of studies have reported decreased Aβ1-42, and increased T-tau and P-tau levels in CSF of MCI and AD patients.

    “Majority of studies have reported decreased Aβ1-42, and increased T-tau and P-tau levels in CSF of MCI and AD patients (Hansson et al., 2006; Mattsson et al., 2009; Andreasen et al., 2001, 2003) and our findings are in conformity with those studies.”

    From T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease (2015) · cites this paper as Hansson et al., 2006

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L.
Affiliations
  • Lund University (SE)
  • Sahlgrenska University Hospital (SE)
Corresponding author
Blennow, Kaj
ORCID
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2006-03
Volume
5
Issue
3
Pages
228-234
ISSN
1474-4422 (ISSN-L)
DOI
10.1016/s1474-4422(06)70355-6
OpenAlex
W2161737267
Cited by
1,700
References
43
Citations by year
2026: 28 · 2025: 40 · 2024: 47 · 2023: 43 · 2022: 70 · 2021: 55 · 2020: 114 · 2019: 63 · 2018: 93 · 2017: 60 · 2016: 76 · 2015: 94 · 2014: 109 · 2013: 100 · 2012: 122
FWCI
68.81
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
Keywords
Alzheimer's disease, mild cognitive impairment, cerebrospinal fluid biomarkers, amyloid-beta 42, total tau, phosphorylated tau 181, conversion to dementia, early detection of Alzheimer's disease, sensitivity and specificity, risk factors
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Analysis of Variance, Cognition Disorders, Dementia, Female, Follow-Up Studies, Humans, Male, Middle Aged, Peptide Fragments, Phosphorylation, Psychiatric Status Rating Scales, Retrospective Studies, Time Factors, Biomarkers, Chi-Square Distribution, Odds Ratio, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review